Cesium-131 GammaTile improves surgical bed control versus postoperative stereotactic RT in phase III trial

ROADS phase III found 1.3% versus 15.4% surgical bed recurrence at 12 months with cesium-131 tiles versus postoperative stereotactic RT.

KEY POINTS

  • ROADS (NCT04365374) was a randomized, open-label, phase III noninferiority trial conducted across 32 US centers, comparing surgical resection followed by intraoperative cesium-131 tile-based radiation therapy (TBRT) with resection followed by postoperative stereotactic radiation therapy (SRT). Between April 2021 and August 2025, 230 patients were randomized, with 204 included in the prespecified modified intention-to-treat population: 103 assigned to TBRT and 101 to SRT. Eligible patients had a resectable brain metastasis measuring 2–7 cm, with up to five additional nonresected metastases.
  • TBRT delivered radiation immediately after resection using permanent cesium-131 collagen tiles, each containing four sealed radioactive sources. Postoperative SRT was prescribed according to cavity size as 17–20 Gy in one fraction, 27 Gy in three fractions, or 30 Gy in five fractions, with treatment planned approximately three weeks after surgery. The median actual interval from surgery to SRT initiation was 27 days, while additional nonresected metastases were treated with SRT in both groups.
  • The co-primary endpoint of surgical bed recurrence strongly favored TBRT. Only one patient in the TBRT group developed surgical bed recurrence compared with 12 patients in the SRT group. Median time to recurrence was not reached with TBRT versus 17.4 months with SRT, corresponding to HR 0.06 (95% CI 0.01–0.46; p=0.0070) in superiority testing. At 12 months, the cumulative incidence of surgical bed recurrence was 1.3% versus 15.4%, an absolute difference of 14.1 percentage points.
  • Surgical bed recurrence-free survival also improved significantly. There were 30 events with TBRT versus 45 with SRT, and median surgical bed recurrence-free survival was not reached versus 10.9 months, respectively (HR 0.48, 95% CI 0.30–0.76; p=0.0021). The prespecified hierarchical testing procedure demonstrated both noninferiority and superiority for the two co-primary endpoints.
  • Overall survival was longer in the modified intention-to-treat analysis, with median survival of 42.5 months after TBRT versus 17.6 months after SRT (HR 0.59, 95% CI 0.37–0.96; p=0.032). This finding requires caution because 18 patients assigned to postoperative SRT did not receive that treatment, including eight who died before SRT, whereas all 103 patients in the TBRT efficacy population received their assigned irradiation. In the per-protocol analysis, the OS difference was no longer statistically significant (HR 0.73; p=0.216).
  • Improved surgical bed control did not result in greater observed radionecrosis. At 12 months, cumulative radiation necrosis incidence was 5.3% with TBRT versus 5.7% with SRT (HR 0.85; p=0.76). Distant brain failure was similar (HR 0.93; p=0.79), with no significant difference in leptomeningeal disease. Quality of life, functional status, and neurocognitive assessments also showed no significant between-group differences during available follow-up.
  • Severe treatment-related adverse events were comparable between strategies. Grade ≥3 treatment-related events occurred in 20.0% of TBRT recipients versus 21.7% of SRT recipients, while any adverse events occurred in 79.0% versus 80.7%, respectively. Interpretation is limited by median follow-up of 12.9 months, treatment-adherence differences, and the modified intention-to-treat population, which excluded patients without surgery, appropriate pathology, or follow-up. The original primary endpoint definition was also corrected during the trial, before independent central efficacy review.

CLINICAL TAKEAWAY

ROADS provides randomized phase III evidence that intraoperative cesium-131 tile brachytherapy improves surgical bed control compared with postoperative SRT for selected resectable brain metastases, without an apparent increase in early radionecrosis or severe toxicity. The immediate delivery of radiation also addresses the clinically important interval between surgery and postoperative SRT. Longer follow-up and careful interpretation of treatment-adherence differences are needed, particularly before attributing the observed overall survival advantage entirely to the radiation technique.

SOURCE

Journal of Clinical Oncology

Browse more research Suggest a correction